- Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
- Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
- Kymera Therapeutics to Participate in Upcoming June Investor Conferences
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
- Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
- Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
- Kymera Therapeutics to Participate in Upcoming May Investor Conferences
- Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
More ▼
Key statistics
On Friday, Kymera Therapeutics Inc (KYMR:NMQ) closed at 30.25, -33.24% below its 52-week high of 45.31, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 30.06 |
---|---|
High | 30.43 |
Low | 29.74 |
Bid | 29.18 |
Offer | 33.95 |
Previous close | 30.16 |
Average volume | 690.44k |
---|---|
Shares outstanding | 61.36m |
Free float | 60.55m |
P/E (TTM) | -- |
Market cap | 1.85bn USD |
EPS (TTM) | -2.50 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼